Drug Trial Radar · NCT06886139
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
139
Planned (sponsor's estimate)
Start
Sep 2025
Primary completion
Jan 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Zhejiang Teruisi Pharmaceutical Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, open-label, single-arm, Phase II Study. Patients with CD20 positive recurrent or refractory diffuse large B-cell lymphoma and had failed ≥2 prior lines of standard treatment will be recruited. The purpose of this trial is to evaluate the efficacy, safety, pharmacokinetic (PK) and immunogenicity characteristics of TRS005 via intravenous drip.
Conditions
- CD20-positive Diffuse Large B-Cell Lymphoma
Interventions
TRS005Drug
Recombinant anti-CD20 monoclonal antibody-MMAE conjugte for injection. To be used under medical supervision.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR, Objective Response RateTime frame: At the end of cycle 2, cycle 4, cycle 6 and every 4 subsequent cycles (each cycle is 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences, Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.